KENILWORTH, N.J.--(<a href="http://www.businesswire.com">BUSINESS WIRE</a>)--The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable and underserved Southeastern U.S. communities.While new cases of HIV are on the decline in the U.S., HIV continues to disproportionately affect certain populations and geographic regions of the country. According to the U.S. Centers for Disease Control and Prevention, over half of all people newly diagnosed with HIV live in the U.S. South, with approximately three quarters of them identifying as people of color.To help improve the delivery of HIV care and address persistent health disparities, HIV Care Connect will support community-based programs that promote linkage to and long-term engagement in HIV care as well as foster multisectoral approaches to address the many factors outside the health system that affect access to high-quality care.&ldquo;We need to accelerate solutions that address the growing disparities in patients&rsquo; access to HIV care and health outcomes, and focus on communities that are most affected,&rdquo; said Dr. Julie Louise Gerberding, executive vice president and chief patient officer at Merck. &ldquo;Through HIV Care Connect, the Merck Foundation is helping to catalyze collaboration among organizations across the southeastern United States and improve care coordination among people most affected by HIV.&rdquo; The Foundation has selected the following organizations as HIV Care Connect program grantees.<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.uab.edu%2Fhome%2F&amp;esheet=52087387&amp;newsitemid=20190904005088&amp;lan=en-US&amp;anchor=The+University+of+Alabama+at+Birmingham&amp;index=4&amp;md5=d3c0280ae905040a54bdf756f070ee5a">The University of Alabama at Birmingham</a> will serve as the National Program Office for HIV Care Connect. In this capacity, it will support the program efforts of the grantee organizations and provide leadership in building a public-private partnership to reduce disparities in HIV care.&ldquo;We believe the HIV Care Connect initiative has the potential to be transformative in our region,&rdquo; said Michael Mugavero, MD, MHSc, professor of medicine, University of Alabama at Birmingham (UAB) and co-director, UAB Center for AIDS Research. &ldquo;The program will serve as a catalyst in advancing the objectives of the National HIV/AIDS Strategy and the Ending the HIV Epidemic Federal initiative.&rdquo;HIV Care Connect program grantees will implement multifaceted, evidence-based programs to:<ul><li>Improve linkage to and retention in high-quality HIV care for populations most affected by HIV</li><li>Build sustainable collaborations between the health care sector and other sectors to address barriers related to the social determinants of health</li><li>Engage the community in program development to ensure that interventions are effectively tailored to address local needs</li><li>Improve health outcomes for persons living with HIV, particularly in underserved communities</li></ul>The Foundation will support an independent evaluation to assess the impact of the HIV Care Connect initiative and its programs. A key goal will be to identify and promote best practices for improving the delivery of HIV care among vulnerable and underserved U.S. communities.Improving Access to CareMerck is committed to discovering smart, sustainable ways to expand global access to health care and, through the Merck Foundation, supports innovative partnerships and approaches to improve the health of vulnerable and underserved populations. The new HIV Care Connect initiative follows other investments by the Foundation to reduce health disparities and improve access to high-quality health care, such as the $16 million, five-year initiative <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.msdresponsibility.com%2Faccess-to-health%2Fkey-initiatives%2Fbridging-the-gap-diabetes%2F&amp;esheet=52087387&amp;newsitemid=20190904005088&amp;lan=en-US&amp;anchor=Bridging+the+Gap+in+Diabetes+Care&amp;index=5&amp;md5=e911b88ef5c82e599608a8b744705198"> Bridging the Gap in Diabetes Care </a> .

The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable and underserved Southeastern U.S. communities. While new cases of HIV are on the decline in the...

Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities

Key Takeaways
AS01-adjuvanted vaccines, Arexvy and Shingrix, are linked to a reduced dementia risk, increasing dementia-free time by up to 37%.
The study found no significant difference in dementia risk reduction between receiving one or both AS01 vaccines.
New study findings published by investigators in Nature found that 2 AS01-adjuvanted vaccine

Shingles and RSV Vaccines Show Promise Against Dementia

“Patient-reported outcomes and quality of life [were] the same in both groups [for durvalumab plus FLOT and FLOT alone], once again highlighting the feasibility of this regimen as [a potential] new standard globally for [resectable] gastric and gastroesophageal adenocarcinoma.”
Yelena Y. Janjigian, MD, chief of the Gastrointestinal Oncology Service

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

Baseline characteristics from CARTITUDE-1 reflect a high-risk, refractory population. Approximately 15% had extramedullary disease and 25% had high-risk cytogenetics. The median prior lines of therapy was 6, with nearly all patients refractory to their last regimen.
This highlights the aggressive disease biology and treatment resistance among parti

CARTITUDE-1 Baseline Demographics

Summary
Background
During the COVID-19 pandemic, vulnerable groups faced a higher risk of severe COVID-19 outcomes. The effect of the pandemic on adult childhood cancer survivors is a significant public health concern but not sufficiently understood. We aimed to assess whether adult childhood cancer survivors had a higher risk of severe COVID-19 an

COVID-19 infection and severity among childhood cancer survivors in Denmark and Sweden: a register-based cohort study with matched population and sibling comparisons

July 4, 2025
Background/Significance
Financial toxicity is the burden faced from out-of-pocket costs, which affects quality of life and possibly survival. Maimonides Medical Center serves a diverse population, including patients from marginalized groups who may be vulnerable to financial toxicity. Here, we present a preliminary analysis of change i

13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

The addition of topotecan (Hycamtin) to obrixtamig (BI 764532) exhibited tolerability and promising preliminary efficacy in patients with advanced extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1 DAREON®-9 trial (NCT05990738) from a poster presented at the 2025 American Society of Clinical Oncology (ASCO) Ann

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Researchers found no evidence of a causal relationship between most drugs previously implicated in microscopic colitis risk -- including nonsteroidal anti-inflammatory drugs (NSAIDs), proton-pump inhibitors, and statins -- and researchers said a small association with selective serotonin receptor inhibitors could come down to surveillance bias. (An

NSAIDs and Microscopic Colitis; Fundoplication for GERD; Novel Drug Succeeds in MASH

1. In this randomized clinical trial of adults with type 2 diabetes (T2D), the artificial intelligence-based insulin clinical decision support system (iNCDSS) was noninferior to standard physician-administered insulin therapy.
2. Compared to the physician group, there were no significant differences in adverse events in the iNCDSS group.
Evidence R

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

In the recurrent metastatic setting, certain patient populations warrant caution when considering PD-1 inhibitors as first-line therapy. Patients with preexisting autoimmune diseases are a key group where for which careful assessment is needed. While those with well-controlled autoimmune conditions might still be candidates, the risk of immune-rela

Perspectives on Treatment Choices - From Clinical Evidence to Decision-Making

Previous Abstract
Research Letter
The GENIFEM Pilot Randomized Trial: Genicular Nerve Block vs Femoral Triangle Block vs Local Infiltration Analgesia for Total Knee Arthroplasty
Belba, Amy MD1,2,3; Peene, Laurens MD1; Mesotten, Dieter MD, PhD1,2; Vanlommel, Luc MD4; Van Zundert, Jan MD, PhD1,2,5; Vanneste, Thibaut MD1,2,5; Collaborators
Author Info

The GENIFEM Pilot Randomized Trial: Genicular Nerve Block vs Femoral Triangle Block vs Local Infiltration Analgesia for Total Knee Arthroplasty

In Part 2 of our interview with Clemson University microbiome researchers Anna Seekatz, PhD, and PhD candidate Sophie Millard, we explore the deeper mechanisms behind why fecal microbiota transplantation (FMT) sometimes fails, even when donor microbes appear to successfully colonize the host gut.
Their new study, published in mBio, highlights a cri

Moving Beyond One-Size-Fits-All: The Future of Microbiome Therapy for C diff and Beyond

Video-based genetic counseling led to improved comprehension by the advice seeker and a reduction in physician counseling duration when patients underwent physician-led counseling for hereditary breast and ovarian cancer (HBOC), according to results from a study shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1
Overal

Video-Based Genetic Counseling Improves Comprehension in HBOC

Cook Medical has initiated a Class I recall of its Beacon Tip 5Fr angiographic catheter.
This follows reports of tip separation that could result in serious injury or death. The recall, identified as the most serious type by the US Food and Drug Administration (FDA), involves the removal of affected devices from clinical and commercial use.
In its

Cook Medical issues Class I recall for Beacon Tip angiographic catheters

Adding polatuzumab vedotin to treatment with rituximab, gemcitabine, and oxaliplatin (R-GemOx) can improve survival outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to phase 3 trial results presented at the EHA 2025 Congress.
The phase 3 trial, POLARGO (NCT04182204), included 270 patients with relapsed/

Polatuzumab Vedotin Improves PFS, OS in Rel/Ref DLBCL

"Lifileucel TIL therapy [is an FDA-approved option] for patients who either do not respond to immune checkpoint inhibitor therapy or develop resistance to it."
Theresa Medina, MD, a medical oncologist specializing in melanoma at the University of Colorado Cancer Center–Anschutz Medical Campus, discussed the long-term efficacy and safety of lifileuc

Dr Medina on the Long-Term Efficacy and Safety of Lifileucel TIL Therapy in Advanced Melanoma

Combining bemarituzumab with leucovorin calcium, fluorouracil, and oxaliplatin (mFOLFOX6) as frontline therapy demonstrated a statistically significant and clinically meaningful overall survival (OS) improvement vs placebo plus mFOLFOX6 among patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

The 1-year progress free survival and complete remission rates were both 88%. The overall survival rate was 94%.
The combination of low-dose nivolumab with bendamustine in treatment of children with high-risk relapsed/refractory classical Hodgkin lymphoma (rrHL) appeared to be associated with favorable survival and response outcomes. Study results

Low-Dose Nivolumab and Bendamustine Improves Outcomes for Pediatric R/R Hodgkin Lymphoma

Contact

Advertise

Other industries

Empower vascular access teams with tools that streamline workflows, enhance teamwork, and improve outcomes.

Tools for Efficient Vascular Access | Salubrity Online

Gebauer’s Pain Ease® works in just 4-10 seconds!

Give patients the comfort they deserve

Ivenix Infusion System

You have several options—but you also have several reasons to choose one above the rest.
Learn more now.


Prescribing IVIg?

AVA Consensus Statement recommend adhesives like gum mastic to secure PIVC dressings and devices.